From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
USA News Group – News Commentary
The AI revolution in healthcare is fully underway, promising not only better health outcomes but also major cost savings. Healthcare startups are increasingly integrating AI tools to scale patient services and boost profitability, which is catching the attention of investors. With regulatory progress accelerating, many of these technologies are now nearing real-world deployment.
Currently, the AI in healthcare market is projected to surpass $110 billion by 2030. According to Accenture, artificial intelligence could unlock an additional $461 billion in value by 2035—on top of a sector already expected to exceed $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI), in collaboration with Ainnova Tech, continues to gain traction with their AI-powered diagnostic platform. At Roche’s recent Macular Spectacular conference in Colombia, Vinicio Vargas, CEO of Ainnova, presented Vision AI—a tool to expand access to diabetic retinopathy screening and prevent blindness. The project, piloted with Roche and Salud 360, may soon launch in the U.S., Canada, and Europe.
A major milestone was reached following a pre-submission meeting with the FDA, preparing the way for 510(k) clearance. The U.S. trials, supported by clinical partner Fortrea, will evaluate Vision AI by comparing its results to those of three retinologists.
“We’re truly excited about this next phase,”
said Vinicio Vargas, CEO of Ainnova and board member of Ai-nova Acquisition Corp.
“We believe [our automated retinal camera] will be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care.”
Meanwhile, in Latin America, the system is already live via pharmacy chains Fischel and La Bomba, offering walk-in screenings with real-time AI results.
Over 30% of diabetics develop retinopathy, a leading cause of preventable blindness. Vision AI provides early, affordable detection without requiring an ophthalmologist onsite.
Avant, through Ai-nova Acquisition Corp., holds global licensing rights to Ainnova’s technology. A potential full acquisition of Ainnova by Avant remains under consideration to streamline operations and give investors clearer exposure to this rapidly evolving field.
Ainnova’s roadmap includes tools for early detection of Alzheimer’s, cardiovascular conditions, and other chronic diseases through retinal and blood biomarkers.
Other notable developments in AI healthcare include:
Agenus Inc. (NASDAQ: AGEN) is working with Noetik, an AI biotech firm, to develop predictive biomarkers for its immunotherapy platform.
“This collaboration enables us to harness cutting-edge AI to better understand patient biology,”
said Dr. Garo Armen, Chairman and CEO of Agenus.
Clover Health (NASDAQ: CLOV) launched an AI-driven pharmacy pilot in New Jersey through the IPC iCare+ network, helping seniors manage medication and reduce hospitalizations.
“This is more than a program—it’s a new model,”
said Jamie Reynoso, CEO of Medicare Advantage at Clover.
Zimmer Biomet (NYSE: ZBH) announced the acquisition of Monogram Technologies (NASDAQ: MGRM) for $177 million, with milestone-based payments to follow. The move adds semi- and fully-autonomous orthopedic robotics to its ROSA® platform.
“With Monogram’s technology, we aim to redefine orthopedic surgery,”
said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.
Monogram’s FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development.
“We are thrilled to join Zimmer Biomet’s world-class ecosystem,”
added Benjamin Sexson, CEO of Monogram.
Zimmer expects the deal to become accretive by 2028, strengthening its long-term position in the high-demand robotics surgery market.
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits, source
Read the latest AI news at thinkaivolution.com
